This Article Full Text (PDF) All Versions of this Article: 1087054707306109v1 11/4/470    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Spencer, T. J. Articles by Mintz, M. Search for Related Content PubMed PubMed Citation Articles by Spencer, T. J. Articles by Mintz, M. Social Bookmarking                         What's this?

Atomoxetine Treatment of ADHD in Children With Comorbid Tourette Syndrome

Massachusetts General Hospital, tspencer{at}partners.org

F. Randy Sallee

Cincinnati Children's Hospital

Donald L. Gilbert

Cincinnati Children's Hospital

David W. Dunn

Indiana University School of Medicine

James T. McCracken

Neuropsychiatric Institute, Los Angeles

Barbara J. Coffey

New York University Child Study Center

Cathy L. Budman

North Shore University Hospital, Long Island Jewish Health System

Randall K. Ricardi

Arizona Family Resource and Counseling Center

Henrietta L. Leonard

Rhode Island Hospital, Brown University

Albert J. Allen

Lilly Research Laboratories

Denai R. Milton

Lilly Research Laboratories

Peter D. Feldman

Lilly Research Laboratories

Douglas K. Kelsey

Lilly Research Laboratories

Daniel A. Geller

McLean Hospital, Harvard Medical School

Steven L. Linder

Dallas Pediatric Neurology Associates

Donald W. Lewis

Monarch Research Associates

Paul K. Winner

Premiere Research Institute, Palm Beach Neurology

Roger M. Kurlan

University of Rochester School of Medicine and Dentistry

Mark Mintz

Clinical Research Center of New Jersey, The Center for Neurological and Neurodevelopmental Health

Objective: This study examines changes in severity of tics and ADHD during atomoxetine treatment in ADHD patients with Tourette syndrome (TS). Method: Subjects (7-17 years old) with ADHD (Diagnostic and Statistical Manual of Mental Disorders, DSM-IV) and TS were randomly assigned to double-blind treatment with placebo (n = 56) or atomoxetine (0.5-1.5 mg/kg/day, n = 61) for approximately 18 weeks. Results: Atomoxetine subjects showed significantly greater improvement on ADHD symptom measures. Treatment was also associated with significantly greater reduction of tic severity on two of three measures. Significant increases were seen in mean pulse rate and rates of treatment-emergent nausea, decreased appetite, and decreased body weight. No other clinically relevant treatment differences were observed in any other vital sign, adverse event, laboratory parameter, or electrocardiographic measure. Conclusion: Atomoxetine is efficacious for treatment of ADHD and its use appears well tolerated in ADHD patients with comorbid TS. (J. of Att. Dis. 2008; 11(4) 470-481)

Key Words: atomoxetine • ADHD • tic disorders • Tourette syndrome

This version was published on January 1, 2008

Journal of Attention Disorders, Vol. 11, No. 4, 470-481 (2008)
DOI: 10.1177/1087054707306109


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. K. Whalen, B. Henker, S. S. Ishikawa, N. A. Emmerson, R. Swindle, and J. A. Johnston Atomoxetine Versus Stimulants in the Community Treatment of Children With ADHD: An Electronic Diary Study J Atten Disord, January 1, 2010; 13(4): 391 - 400. [Abstract] [PDF]

				G. Bates Drug treatments for attention-deficit hyperactivity disorder in young people Adv. Psychiatr. Treat., May 1, 2009; 15(3): 162 - 171. [Abstract] [Full Text] [PDF]